What Is the Life Expectancy for Stage 2 Kidney Disease?

Most people with stage 2 chronic kidney disease (CKD) can expect to live for many years, and often close to a normal lifespan, but the honest answer depends almost entirely on what else is going on in the body. Stage 2 CKD means kidney filtration has dipped only mildly, to an estimated glomerular filtration rate (eGFR) between 60 and 89 mL/min. At that level, the kidneys are still doing most of their job. The real question is not the stage number on a lab report but whether the kidneys are leaking protein, whether diabetes or high blood pressure is present, and how aggressively those conditions are being managed.

Why a Single Number Is Hard to Give

You will not find a neat table that says “stage 2 CKD = X years of life remaining,” and there is a good reason for that. Large registry data from Alberta, Canada, show that the measurable reduction in life expectancy associated with kidney disease becomes a continuous, detectable trend once eGFR drops below about 60 mL/min, which is the boundary of stage 3, not stage 2.¹ In other words, at stage 2 levels of kidney function, the kidneys themselves are not yet driving a large statistical loss in life expectancy the way they do in later stages.

That does not mean stage 2 is harmless. It means the main threats to longevity at this stage come not from the kidney filtration rate itself but from the underlying disease causing it and from the cardiovascular damage that often tags along. Two people with identical eGFR values can have wildly different outlooks depending on whether they have diabetes, uncontrolled hypertension, or significant protein in the urine. One study estimated that early CKD on its own shortens life expectancy by roughly six years, but when diabetes is also involved, the combined effect reaches about sixteen years, far worse than what either condition would do alone.²

Albuminuria Changes Everything

If there is one test result that matters more than the eGFR number for stage 2 prognosis, it is whether your urine contains abnormal amounts of albumin, a protein that healthy kidneys keep in the blood. Albuminuria is a sign that the kidney’s filtering units are already damaged at a level that the eGFR alone does not capture.

A large cohort study found that people with stage 2 CKD and albuminuria faced roughly a 50 percent higher risk of dying from any cause compared with healthy controls, along with a 32 percent higher risk of a major cardiovascular event and a 79 percent higher risk of heart failure.³ Those hazard ratios were comparable to what researchers saw in stage 3A CKD without albuminuria. In plain terms, a stage 2 diagnosis with protein in the urine carries the same mortality risk as a stage 3A diagnosis without it. That is a striking finding, and it means the staging system alone can be misleading. If your doctor has told you that you have stage 2 CKD but has not checked for albuminuria, you are missing a critical piece of the picture.

Cardiovascular Disease, Not Kidney Failure, Is the Main Danger

People often hear “kidney disease” and immediately think of dialysis. At stage 2, the realistic worry is not that your kidneys will fail anytime soon. The far more likely threat to life expectancy is cardiovascular disease. Heart attacks, strokes, and heart failure are the leading causes of death in CKD at every stage, and the risk begins to climb well before the kidneys are anywhere near failure.

The link between even mildly reduced kidney function and heart trouble is partly why albuminuria matters so much: it is both a kidney marker and a vascular marker. Leaky kidneys often signal leaky blood vessels throughout the body. The cohort study cited above showed that heart failure risk nearly doubled in stage 2 CKD patients who had albuminuria, and major adverse cardiovascular events rose by about a third.³ The practical takeaway is that managing cardiovascular risk factors, blood pressure, cholesterol, blood sugar, and smoking, may do more for longevity in stage 2 CKD than focusing on the kidney number alone.

Stage 2 as a Biological Tipping Point

One emerging line of research suggests that stage 2 CKD is more biologically significant than its mild-sounding label implies. A proteomic study comparing blood samples across all five CKD stages found that the transition from stage 1 to stage 2 involved distinctive changes in inflammatory, immune, and metabolic pathways that were not simply a gradual continuation of what came before.⁴ The researchers proposed that stage 2 may represent a critical inflection point, a moment when the body’s compensatory mechanisms start to falter and disease progression accelerates.

This is early research, not yet something that changes clinical guidelines, but it aligns with the cardiovascular data showing that risk rises faster than you would expect from the eGFR drop alone. If stage 2 really is a tipping point, it would make the case for aggressive intervention at this stage even stronger rather than treating it as a “watch and wait” diagnosis.

When Diabetes Is in the Mix

Diabetes deserves its own discussion because it so drastically changes the prognosis. The study that estimated life expectancy losses found that people with both diabetes and early kidney involvement, defined as mildly reduced eGFR or albuminuria, had a three-fold higher death rate compared with people who had neither condition. That translated to roughly sixteen years of life lost.² Importantly, the mortality rate for people with diabetic kidney disease was nearly twice as high as the rate for people with early CKD alone and also nearly twice the rate for people with diabetes but no kidney involvement. The combination is far worse than the sum of its parts.

Most of those people were unaware of their kidney involvement, which is a recurring theme in stage 2 CKD. Because symptoms are rarely present and the eGFR number still looks close to normal, many patients are never told they have kidney disease at all, or they are told not to worry about it. The evidence suggests they should be worrying, or at least their doctors should.

Is Your eGFR Even Accurate?

Part of the uncertainty around stage 2 prognosis comes from the limitations of the standard blood test used to estimate kidney function. The most common method relies on creatinine, a waste product of muscle metabolism. But creatinine levels are influenced by muscle mass, diet, age, and other factors that have nothing to do with the kidneys. In a muscular young person, creatinine can overestimate kidney function. In an older, smaller-framed person, it can make things look better than they are.

Research across diverse populations has shown that an alternative blood marker called cystatin C is better at predicting who will actually get sick or die. A meta-analysis involving more than 90,000 participants found that reclassifying people based on cystatin C rather than creatinine meaningfully improved the prediction of death and kidney failure.⁵ A separate study confirmed that adding cystatin C to a model that already included creatinine and urine albumin still improved the accuracy of predicting both death and progression to end-stage kidney disease.⁶

More recent work found that cystatin C–based estimates were better at predicting cardiovascular events and death in both older and younger adults, while the standard creatinine-based eGFR added essentially zero predictive value for cardiovascular disease on top of traditional risk factors.⁷ The practical implication: if you have been told you have stage 2 CKD based on creatinine alone, your true risk could be higher or lower than that label suggests. If your doctor has not checked cystatin C or urine albumin, asking for those tests may give you a much clearer sense of where you actually stand.

The Age Factor

Kidney function naturally declines with age, and the current diagnostic framework for CKD does not adjust for that. A systematic review of age-related kidney function decline confirmed that eGFR falls progressively as people get older, yet the definition of CKD uses a fixed cutoff of 60 mL/min without any age correction.⁸ This means a healthy 75-year-old with an eGFR of 65, which technically qualifies as stage 2, may simply have age-appropriate kidney function rather than a disease that threatens their lifespan.

On the flip side, a 35-year-old with the same eGFR likely has something genuinely wrong and decades of potential decline ahead. The context around who you are matters as much as the number itself. If you are over 65 and your eGFR is in the low-to-mid stage 2 range with no albuminuria and no underlying disease, the prognosis is very different from a younger person with the same number plus diabetes and protein in the urine.

What You Can Do to Improve the Outlook

The encouraging side of stage 2 CKD is that there is a wide window for intervention. Because the kidneys are still functioning relatively well, the choices you make now can meaningfully alter the trajectory.

Blood pressure control is one of the best-studied interventions. A long-term follow-up of patients with CKD found that stricter blood pressure targets were protective against both progression to end-stage kidney disease and death, though the benefit was most pronounced in certain subgroups: people with significant proteinuria, those over 40, and those with obesity.⁹ Crucially, aggressive blood pressure lowering was not associated with increased harm in any subgroup, so the downside risk appears low even if the benefit for some individuals is modest.

More broadly, controlling multiple cardiovascular risk factors at once, blood pressure, blood sugar, cholesterol, and weight, appears to reduce the risk of heart attack, stroke, CKD progression, and death in a dose-dependent way. The more risk factors you bring under control, the greater the cumulative benefit.¹⁰

Lifestyle behaviors also play a role, though the direct evidence for slowing CKD progression specifically through diet, exercise, or weight management is thinner than you might expect from how often these recommendations appear. A narrative review noted that large trials demonstrating that lifestyle changes slow eGFR decline are still lacking, but the authors emphasized that the cardiovascular benefits of a healthy lifestyle are well established and remain a cornerstone of CKD management given how much of the mortality risk comes from the heart rather than the kidneys.¹¹

Medications That May Help

Several classes of medication have been studied in people with CKD, with mixed results depending on the stage and underlying cause.

ACE inhibitors and ARBs, the blood-pressure-lowering drugs commonly prescribed for kidney protection, were associated with about a 19 percent lower risk of death in a large analysis that included CKD patients across all stages.¹² However, a Cochrane review focused specifically on early-stage, non-diabetic CKD found low-certainty evidence that these drugs may make little difference to death or cardiovascular events in that particular group.¹³ The discrepancy likely reflects the fact that people with early, non-diabetic CKD are already at lower risk, so the absolute benefit of these drugs is smaller. If you have diabetes or significant proteinuria, the case for ACE inhibitors or ARBs is much stronger.

SGLT2 inhibitors, originally developed for diabetes, have rapidly become important in kidney disease management. A study of patients with type 2 diabetes and stage 1 through 3 CKD found that SGLT2 inhibitors were associated with a lower incidence of mineral and bone metabolism complications compared with another diabetes drug class, on top of their known benefits for slowing kidney decline and reducing heart failure risk.¹⁴ SGLT2 inhibitors are increasingly prescribed even in non-diabetic CKD, and guidelines have expanded their use in recent years. If you have stage 2 CKD and have not discussed this class of drugs with your doctor, it may be worth raising.

Sex Differences in CKD Outcomes

Men and women experience CKD differently in ways that affect both diagnosis and prognosis. Population studies indicate that women have a higher overall prevalence of CKD yet experience fewer cardiovascular events than men at every CKD stage, though this female advantage narrows or disappears entirely in people on dialysis or after transplantation.¹⁵ The reasons are likely a mix of hormonal, metabolic, and behavioral factors. Women are more likely to be diagnosed with CKD in part because creatinine-based formulas can overestimate kidney function in men with higher muscle mass, and women tend to have lower baseline eGFR values that cross diagnostic thresholds more easily.

For men with stage 2 CKD, the higher cardiovascular risk that comes with being male is layered on top of whatever kidney-related risk exists. For women, the lower cardiovascular event rate is reassuring but does not eliminate the need for monitoring, especially since the gap shrinks as kidney disease advances. Neither sex should treat a stage 2 diagnosis as negligible, but the urgency of cardiovascular risk management is arguably even higher for men.

What Monitoring Looks Like Going Forward

If you have stage 2 CKD, the monitoring schedule typically involves periodic blood and urine tests to watch for changes in eGFR and albumin levels. How often these are needed depends on the cause of the kidney disease and whether other risk factors are present. Someone with isolated stage 2 CKD, no albuminuria, no diabetes, and well-controlled blood pressure might need testing only once a year. Someone with albuminuria or diabetes might need checks every three to six months.

The trajectory matters more than any single snapshot. A stable eGFR in the 70s over several years is a very different picture from an eGFR that has been steadily dropping by three or four points per year. If your eGFR is declining faster than expected for your age, that warrants a conversation about causes and interventions even if the current number still falls within the stage 2 range. Conversely, a steady reading at this stage, especially in someone over 60 without proteinuria, is genuinely reassuring and consistent with a near-normal life expectancy.